Title: Cost, cost-effectiveness and budget impact analysis of near point-of-care GeneXpert testing for

STIs in South Africa: leveraging current capacity to address high prevalence of *Chlamydia trachomatis*,

Neisseria gonorrhoeae and *Trichomonas vaginalis*

Short title: Optimising STIs screening through near-POC GeneXpert testing in South Africa

Nkgomeleng Lekodeba * [a,] Katherine Snyman* [a, b], Brooke E Nichols [a, c, d], Lise Jamieson [a, e]

a. Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the

Witwatersrand, Johannesburg, South Africa.

b. Department of Global Health and Development, London School of Hygiene and Tropical Medicine,

London, United Kingdom

c. Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

d. Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam

UMC, University of Amsterdam, Amsterdam, Netherlands.

e. South African Department of Science and Innovation/National Research Foundation Centre of

Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch,

South Africa.

*Contributed equally to this paper

Corresponding author: Nkgomeleng Lekodeba; Health Economics and Epidemiology Research Office,

Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Building C, First

Floor, Sunnyside Office Park, 32 Princess of Wales Terrace, Parktown, Johannesburg, 2193.

nlekodeba@heroza.org, Tell: +2710 001 7930

NL: nlekodeba@heroza.org

KS: katherine.snyman@lshtm.ac.uk

BEN: brooken@bu.edu

LJ: ljamieson@heroza.org

Key word: Sexually transmitted infections, Point-of-care, GeneXpert testing, cost-effectiveness,

Adolescent girls and young women, Incremental cost-effectiveness ratios

Abstract

Background: South Africa has high sexually transmitted infections (STIs) prevalence and currently

implement syndromic management, which has limitations such as untreated asymptomatic infections

and antibiotic misuse. Diagnostic tools, like GeneXpert may offer potential improvements. We evaluated

costs, cost-effectiveness and budget impact of reallocating GeneXpert capacity for STIs testing.

Methods: We developed static analytical model using previously collected data. Over one-year time

horizon from provider perspective, we compared costs reported in 2024 USD and outcomes of

syndromic management and nine scenarios using near point-of-care GeneXpert testing for *Neisseria*

gonorrhoeae, Chlamydia trachomatis, and *Trichomonas vaginalis* in various target groups, including

symptomatic individuals, antenatal care (ANC) attendees and HIV testers (Adolescent girls and young

women (AGWY), and adults). Univariate sensitivity analysis was conducted to assess uncertainty of key

parameters.

Results: Cost per person treated and correctly treated ranged from $21-$29 (syndromic management)

and $88-$579 in GeneXpert scenarios. Syndromic management cost the healthcare system an estimated

$24 million, GeneXpert testing would cost substantially more: $207 million (symptomatic), $116 million

(ANC attendees), $1.7 billion (HIV testers), and $310-$884 million for targeted/combined approaches

involving ANC attendees, AGWY and symptomatic individuals, and increase number of cases correctly

treated by over 3-fold. Of scenarios modelled, two were cost-effective: 1) AGYW HIV testers and adults

with STI symptoms, and 2) adults (15-49 years) having either HIV test or STI symptoms, incremental cost

per additional case correctly treated was $515 and $1,079, respectively. While they are cost-effective,

they would cost $2.26 and $10.52 billion over 5-years, respectively, compared to $145 million in

syndromic management. Cost of cartridge was most influential parameter in sensitivity analysis.

Conclusions: Prioritizing symptomatic individuals, high-risk groups (i.e HIV testers), and cost-effective

interventions can improve cases correctly treated but requires additional budget. These findings support

the need for targeted strategies to optimise clinical and economic benefits of GeneXpert testing for STIs.

Introduction

Worldwide, four curable sexually transmitted infections (STIs) – syphilis (*Treponema pallidum*), *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT), and *Trichomonas vaginalis* (TV) – account for over 1 million new infections daily, including, annually, 156.3 million new cases of trichomoniasis, 128.5 million new cases of chlamydia, 82.4 million new cases of gonorrhoea, with the majority occurring in low- and middle-income countries (LMIC) (1) . Sub-Saharan Africa (SSA) has a disproportionately high prevalence of these infections the highest age-standardized incidence rates and a greatest number of disability-adjusted life years lost (2), driven by limited access to healthcare, diagnostics, and prevention, as well as socio-economic factors like poverty and gender inequality, which hinder treatment uptake and increase exposure(3,4). South Africa has one of the largest burdens of curable STIs in the world with the prevalence notably higher among adolescent girls and young women (AGYW) and in pregnant women, where reported prevalence of STIS can reach up to 40% (5–11). In addition, South Africa has the largest population of people living with HIV (PLHIV) in the world, with about 8 million PLHIV in 2024 (12). Co-infection with HIV is common, and people living with HIV are more vulnerable to STI infection, further compounding the public health challenge (10). Untreated STIs can lead to severe health consequences, including infertility, pelvic inflammatory disease, ectopic pregnancies, stillbirths, and an increased risk of HIV acquisition and transmission, making them a critical public health concern (13). Gonorrhoea's growing antimicrobial resistance (AMR) further complicates STI control, highlighting the urgency of addressing this issue (14–16). While STIs are preventable, and most are treatable or curable, effective case management and prevention strategies, such as point-of-care diagnostics and clinical treatment protocols, are essential for breaking the transmission cycle.

In South Africa and throughout SSA, syndromic management is the standard approach for curable STIs

(17), but it has limitations, including the high prevalence of untreated asymptomatic infections (18) and

risks of overtreatment and antibiotic misuse (19). The WHO recommends etiological testing for curable

STIs to enhance diagnostic accuracy and improve disease management, especially in LMICs (20). While

syphilis rapid tests are widely used for antenatal screening and are considered highly cost-effective (21–

23), no rapid tests are currently available or used in South Africa for other curable STIs, such as NG, CT,

and TV. In LMICs, where screening for these STIs does occur, Nucleic Acid Amplification Tests (NAATs) or

Polymerase Chain Reaction (PCR) testing are the most common methods, but they are often

prohibitively expensive (24,25). GeneXpert (Cepheid, Sunnyvale, CA, USA) is a PCR-based test that

enables point-of-care (POC) testing for NG, CT, and TV, with options for both off-site and on-site testing.

Studies in South Africa (26) and Botswana (27) reported incremental cost-effectiveness ratios (ICERs) for

various GeneXpert strategies ranging from $93 to $5,445 compared to syndromic management. While

evidence on the cost-effectiveness of POC versus off-site testing for curable STIs in SSA remains limited,

current findings suggest that off-site testing is more cost-effective (24).

Recent studies from South Africa show that off-site GeneXpert testing for *Neisseria gonorrhoeae* (NG)

and *Chlamydia trachomatis* (CT) is both less cost-effective (26) and more-costly (28) compared to on-site

testing using GeneXpert. The GeneXpert diagnostic platform has been in use in South Africa since 2011

as part of an extensive molecular diagnostic program for tuberculosis (TB) (29). Currently, the program is

expanding to incorporate multiple manufacturers, moving beyond reliance on a single platform.

Between April 2022 and March 2023, the National Health Laboratory Service (NHLS) conducted

approximately 2.57 million Xpert MTB/RIF Ultra tests nationwide, which is below the current capacity of

9.7 million tests per year (30). As part of this expansion, it is anticipated that some of the excess

GeneXpert capacity will become available for testing of other infections such as CT, NG and TV (31,32).

In this study, we assessed the potential impact of reallocating excess GeneXpert capacity to test for STIs

with overlapping symptomology, focusing on both cost and health outcomes including the number of

cases correctly and incorrectly treated. We then evaluated the cost, cost-effectiveness and budget

impact of current syndromic management and multiple near-POC GeneXpert testing scenarios for

individuals seeking care for STIs in South Africa.

Materials and Methods

Model structure and approach

Fig 1. The modelling structure and approach*

*Abbreviations: STIs=sexual transmitted infections, ANC=antenatal care; MUS=male urethritis syndrome,

VDS=vaginal discharge syndrome, HIV=human immunodeficiency virus; NG=neisseria gonorrhoea; CT=chlamydia

trachomatis; TV=trichomonas vaginalis; POC = point-of-care

We developed a Microsoft Excel-based static decision analytical mathematical model to estimate cost

and cost-effectiveness of multiple STIs screening strategies, and assessed the budget impact of near-

POC GeneXpert testing for STIs diagnostics (Fig 1). The base case represented the current syndromic

management of STIs, which considers a population of adults aged 15-49 years presenting with vaginal

discharge syndrome (VDS) and male urethritis syndrome (MUS). We constructed multiple hypothetical

scenarios which comprised population-specific scenarios, targeted and/or combination scenarios that

implemented near-POC GeneXpert platforms to screen and test for STIs, including NG/CT and/or TV. For

each scenario, we estimated health outcomes (total number of cases treated, cases correctly treated

and excess antibiotic use) and costs (total health system costs, cost per case treated and correctly

treated). We then used the information to conduct the cost-effectiveness and budget impact analysis.

Modelled scenarios

We modelled near-POC GeneXpert testing scenarios in three broad categories: 1) near-POC syndromic

GeneXpert testing – a set of scenarios testing populations presenting with MUS and VDS; 2) near-POC

opportunistic GeneXpert testing – testing those presenting for their first annual HIV test, or pregnant

women attending antenatal care; 3) Combined and/or targeted near-POC GeneXpert testing scenarios –

a selection of scenarios that were either targeted to specific sub-populations or combined any of the

previously mentioned scenarios. A description of base case and modelled scenarios is shown in Table 1.

Table 1: Summary of modelled scenarios

Testing strategy	Scenario	Description
Syndromic management	Base case	**Syndromic management**: all men and women with STI symptoms seeking care
Near point-of-care syndromic GeneXpert testing scenarios (all scenarios test for NG/CT and TV unless otherwise stated)	S1: Syndromic testing	**GeneXpert testing**: all men and women with STI symptoms seeking care
	S2: Syndromic testing – targeting females	**GeneXpert testing**: all women with STI symptoms seeking care **Syndromic management**: all men with STI symptoms seeking care
	S3: Syndromic testing – NG/CT only	**GeneXpert testing**: all men and women with STI symptoms seeking care (NG/CT testing only)
Near point-of-care	S4: Opportunistic testing - ANC	**GeneXpert testing**: all ANC attendees

Testing strategy	Scenario	Description
opportunistic GeneXpert testing scenarios	S5: Opportunistic testing - HIV testers	**GeneXpert testing**: all men and women presenting for their first HIV test annually
Combined and/or targeted near-POC GeneXpert testing scenarios	S6: Opportunistic testing – AGYW HIV testers	**GeneXpert testing**: women aged between 15-24 years presenting for their first HIV test annually
	S7: Syndromic + Opportunistic (ANC) testing	**GeneXpert testing**: all men and women with STI symptoms seeking care; all ANC attendees
	S8: Syndromic + Opportunistic (ANC + AGYW HIV testers) testing	**GeneXpert testing**: all men and women with STI symptoms seeking care; all ANC attendees; women aged between 15-24 years presenting for their first HIV test annually
	S9: Syndromic + Opportunistic (ANC + HIV testers) testing	**GeneXpert testing**: men and women with STI symptoms seeking care; all ANC attendees; men and women aged 15-24 years those presenting for their first HIV test annually

Abbreviations: ANC=antenatal care; AGYW=adolescent girls and young women; HIV=human immunodeficiency virus; NG=Neisseria gonorrhoea; CT=Chlamydia trachomatis; TV=Trichomonas vaginalis

Input parameters

To inform the parameters for the model, we performed a scoping review of the literature which

evaluated GeneXpert for STI diagnosis in South Africa and throughout SSA for *Chlamydia trachomatis,*

Neisseria gonorrhoea and *trichomonas vaginalis*. We report key model input parameters in Table 2 and

our literature search strategy in S1 Table. Briefly, recent studies conducted in South Africa provided

age- and sex-stratified prevalence for VDS and MUS (33) and for NG, CT and TV (11)and the co-infection

rates of NG and CT (28) (Table 2). For simplicity and considering studies from South Africa found low co-

infection rates with TV, we did not include these in our model (8–10). Prevalence of STIs in women

attending ANC were determined by pooling estimates separately for HIV positive pregnant women

(5,10) and HIV negative pregnant women (7,10), which we incorporated that into our model accordingly.

We obtained the sensitivity and specificity of VDS/MUS (5) for predicting actual STI prevalence, and the

sex-stratified sensitivity and specificity of GeneXpert testing for NG, CT (34) and TV (35). To inform the

size of the target populations across different scenarios, we used several sources. Age- and sex-stratified

South African population data was obtained from Statistics South Africa (12),and the projected number

of HIV testers was obtained from the Thembisa model (36). For the main analysis, we used estimates

from 2024 for both target populations. For antenatal care attendees, we used the annual number of live

births (37) adjusted for the percentage of singleton births (38) and ANC coverage at public health

facilities (39).

Under the base-case syndromic management scenario, we assumed that all primary healthcare (PHC)

attendees presenting with STI symptoms and seeking care would receive and adhere to treatment as per

the *Standard Treatment Guidelines*. These guidelines outline a syndromic approach, which "treats the

signs or symptoms (syndrome) of a group of diseases rather than targeting a specific disease." This

approach enables the simultaneous treatment of one or more conditions that often co-occur and has

been established as the preferred management strategy (17). Our analysis focused on VDS and MUS, as

these clinical symptoms are most commonly associated with NG, CT and TV. While the guidelines also

include lower abdominal pain (LAP) in women as a syndrome associated with these infections, we

excluded it from our model due to insufficient data and to maintain simplicity in the model design (17).

Under all near-POC GeneXpert testing scenarios, different populations were targeted as described in

detail in Table 1, including those with STI symptoms, ANC attendees and HIV testers. We further

assumed that since clients need to return for a next appointment to get their results and treatment,

they were at risk of loss-to-follow-up at a rate of 8%, across all populations in these scenarios (40).

Table 2: Key model input parameters

Parameter	Male	Female	Source
Population parameters			
Population size			(12)
15-19 years	2,757,213	2,729,231	
20-24 years	2,369,402	2,347,230	
25-49 years	12,065,426	12,067,638	
HIV testers (number of people)			(36)

Parameter	Male	Female	Source
15-19 years	456,803	932,464	
20-24 years	807,048	1,352,708	
25-49 years	3,766,765	3,915,335	
** Antenatal care attendees**			(37)
15-49 years	N/A	595,691	
Sensitivity and specificity			
VDS/MUS sensitivity	91.5%	44.9%	(5)
VDS/MUS specificity	60.3%	74.2%	
GeneXpert sensitivity, CT	93.0%	91.0%	(34)
GeneXpert specificity, CT	100.0%	100.0%	
GeneXpert sensitivity, NG	96.0%	93.0%	
GeneXpert specificity, NG	100.0%	100.0%	
GeneXpert sensitivity, TV	89.6%	97.8%	(35)
GeneXpert specificity, TV	99.3%	99.4%	
Epidemiological parameters			
Prevalence of MUS/VDS in PHC attendees			(33)
15-19 years	1.9%	2.2%	
20-24 years	7.3%	5.7%	
25-49 years	3.7%	2.5%	
Prevalence of CT in PHC attendees			
15-19 years	4.7%	14.7%	
20-24 years	8.3%	15.0%	(11)
25-49 years	4.4%	5.6%	
Prevalence of NG in PHC attendees			
15-19 years	1.7%	4.5%	
20-24 years	2.6%	6.1%	
25-49 years	1.8%	2.6%	
Prevalence of TV in PHC attendees			
15-19 years	0.9%	11.2%	
20-24 years	1.7%	15.5%	
25-49 years	6.6%	17.3%	
Proportion all NG and CT cases that are NG/CT co-infections	14.0%	14.0%	(28)
% lost to follow-up after diagnostic test	8.0%	8.0%	(40)
% of live births that are singletons	N/A	98.5%	(38)
% ANC coverage	N/A	94.0%	(39)
% of pregnant women seeking antenatal care	N/A	70.0%	
HIV prevalence in ANC attendees	N/A	27.5%	(41)
Prevalence of NG in ANC attendees	N/A	5.5% (HIV+); 3.1% (HIV-)	Pooled analysis
Prevalence of CT in ANC attendees	N/A	18.3% (HIV+); 20.4% (HIV-)	HIV +: (10)
Prevalence of TV in ANC attendees	N/A	15.1% (HIV+); 10.0% (HIV-)	HIV -:(7,10)
Cost and resource utilization parameters (all costs reported in 2024 USD), applies to males and females			
Standard patient consultation cost	$19.95		(42)
% of PHC visit cost for an asymptomatic case	50%		Assumed
Number of additional time to draw sample for GeneXpert testing	10 minutes		Assumed
Transportation costs to laboratory per sample	$0.11		NHLS personal communication
Registration costs at laboratory per sample	$1.02		(43)
MTB/XDR GeneXpert testing at centralized laboratory	$54.84		
MTB/XDR GeneXpert cartridge	$14.90		(44)
NG/CT GeneXpert cartridge	$16.20		

Parameter	Male	Female	Source
TV GeneXpert cartridge	$19.00		
Collection swab for GeneXpert	$1.52		
% overhead cost at laboratory	10%		(28)
% additional cost for External Quality Assessment at laboratory	4%		Assumed

Cost analysis

We conducted our analysis from the provider perspective, representing the South African Government.

Costs were initially converted to South African Rand (ZAR) in the year of purchase, subsequently inflated

to 2024 ZAR using the consumer price index and converted to United States Dollar (USD) using the

January-June 2024 mean exchange rate (1 USD = 18.7 ZAR), with all costs presented in 2024 USD (45,46).

Clinic-related costs

For syndromic management, we estimated the cost of a clinic consultation using a recent PHC costing

analysis, and used the average visit cost of staff, equipment, consumables, and overheads (42)**.** We

assumed one visit per client, which included triage, screening/diagnosis and treatment. For near-POC

GeneXpert testing scenarios, we assumed that clients with STI symptoms incurred the full cost of a clinic

consultation visit, while asymptomatic clients incurred half the cost. For sample collection, we included

the cost of a GeneXpert collection swab and an additional 10 minutes of consultation time with a

professional nurse at a mid-point pay grade (47). As results would need to be delivered at an additional

visit, we assumed this additional cost at the same rate as a standard patient consultation. Furthermore,

we assumed one day of training for three professional nurses per facility per year, ensuring that at least

one trained nurse is always available in facility and that all nurses will be trained over five years (48).

Laboratory-related costs

Diagnostic costs encompassed expenses related to transportation, sample registration, equipment,

human resources, supplies and materials, overheads, and external quality assessment (EQA) testing. For

testing scenarios which included the use of cartridges for both TV and NG/CT testing, laboratory costs

(excluding cartridges) were assumed to double. Staff, equipment, and consumable costs were based on

a recent costing analysis of MTB/XDR GeneXpert testing conducted in a high-throughput centralized

laboratory within the Gauteng Province (43). We obtained the costs of the GeneXpert cartridges and

swabs from the manufacturer (44). We annualized equipment costs assuming a 5-year working life and a

discount rate of 4% for the annual equivalent cost (43). To adjust for test-specific consumables, the cost

of the MTB/XDR GeneXpert cartridge was subtracted and replaced with the corresponding NG/CT and

TV cartridge costs, as applicable. We have provided the detailed cost input parameters in Table 2.

Treatment costs

Treatment regimens were primarily based on the most recent *South African STI guidelines* (17) but

updated to incorporate new recommendations from the 2024 WHO guidelines (49). We estimated drug

costs using the weighted average contract price (weights were quantity awarded in the government

tender) as recorded in the Current Master Health Product List (50), details of treatment regimens and

their corresponding costs are provided in the S3 Table.

Cost-effectiveness analysis

To determine the final list of scenarios that will remain on the cost-effectiveness frontier, we first

ranked scenarios on total health system costs of from lowest to highest. We identified and eliminated

scenarios that were dominated. A scenario was considered dominated if it resulted in higher total costs

to the healthcare system and fewer number of cases correctly treated to the next highest ranked

scenario. A ICER per additional case correctly treated for each scenario was then calculated by dividing

the difference in total health system costs (incremental cost) by the difference in cases correctly treated

(incremental effect) of one scenario compared to the next best scenario on the cost-effective frontier.

We compared the ICER for each scenario with the ICER of the next best scenario, and those that were

weakly dominated were identified and eliminated. A scenario was considered weakly dominated if it

resulted in smaller effect (lower number of cases correctly treated), but had a higher ICER compared to

the next highest ranked scenario.

Sensitivity analysis

We conducted one-way deterministic sensitivity analysis by varying model input parameters to identify

parameters that were most influential to the ICER per person correctly treated in affecting the cost per

case correctly treated under the base case scenario and ICER per case correctly treated for the scenarios

on the cost-effectiveness frontier. We conducted a univariate deterministic sensitivity analysis by

varying key input costs parameters diagnostic costs (cost of cartridges and EQA), training cost and other

input parameters (sensitivity of syndromic management and near-POC GeneXpert scenarios).

Budget impact analysis

We estimated budget impact for the current syndromic management (base case) and scenarios on the

cost-effectiveness frontier (S5 and S6) over a 5-year period. The 5-year period was chosen to align with

the South African government's medium-term planning which occurs over a period of 5 years. For base

case and each scenario on the cost-effectiveness frontier, we adjusted for input parameters – South

African population (12), HIV testers (36) and ANC attendees (37) annual projections and cost

parameters.

Ethics statement

This study did not require ethics approval because it involved publicly available and previously published data.

Results

Epidemiological health outcomes

The analysis included a total population of 34.3 million male and females aged 15-49 years for the current syndromic management and different GeneXpert testing scenarios. In the base case and near-POC GeneXpert testing (S1-S3), 1.16 million symptomatic individuals were physically examined and tested through near-POC GeneXpert testing platforms, with varying population undergoing physical examinations and near-POC GeneXpert testing, targeted by sex and STIs (Table 3). Near point-of-care opportunistic GeneXpert testing scenarios (S4 and S5) included 595,691 ANC attendees and 11.2 million HIV testers among the overall population. Targeted and/or combined near point-of-care GeneXpert testing scenarios testing (S6) included 2.3 million AGYW and 1.07 million male and females of other age groups presenting with symptoms went through syndromic management. Other targeted and/or combined near point-of-care GeneXpert testing scenarios (S7-S9) expanded coverage, testing 1.73 million (S7), 3.92 million (S8), and 4.88 million (S9) through GeneXpert. A detailed total population included in the base case and all scenario is shown in S2 Figure.

In the base case, all individuals presenting with symptoms were treated for STIs, with 837,239 cases correctly treated, leading to 327,517 cases of excess antibiotic use. In the near-POC syndromic GeneXpert testing scenarios (S1–S3), the number of correctly treated cases was lower due to targeted testing (women only), limited STI testing (NG and CT), and LTFU up to 93,180 cases. In the near-POC

opportunistic GeneXpert testing scenarios, 1.3 million (S4) and 3.1 million (S5) individuals were treated

and of these 992,000 (S4) and 2.78 million (S5) cases correctly treated. In the targeted and combined

near-POC GeneXpert testing scenarios, testing AGYW HIV testers (S6) resulted in 1.8 million individuals

treated, with 1.5 million correctly treated. Testing adults with STI symptoms and ANC attendees (S7)

included 984,410 individuals treated and 932,361 cases correctly treated. Scenarios S8 and S9, with the

highest testing coverage, had up to 1.6 million individuals treated and 1.5 million cases correctly treated,

and LTFU ranging between 318,060 to 399,090 (Table 3). Compared to the base case, S5 was the only

scenario that resulted in an increase in excess ABs use, followed by lower reduction among S4 and S6 of

up to 4% but higher in other GeneXpert testing scenarios (up to 88%).

Cost outcomes

In the base case, the cost per patient visit, excluding treatment, was $20, primarily driven by staff-

related costs (S4 Table). Implementing near-POC GeneXpert testing for NG/CT and TV increased costs to

$166 and $178 per symptomatic and asymptomatic individual (excluding treatment costs) and limiting

testing to NG/CT reduced costs to $97.60 and $110, respectively. Diagnostic costs were the main cost

drivers, accounting for up to75% to 80% for symptomatic and asymptomatic NG/CT and TV testing, and

between 60% to 67% of cost for when testing only asymptomatic and symptomatic NG/CT.

Total costs, cost per person treated and cost per person correctly treated were lowest in the base case

scenario (Table 3). Across GeneXpert testing scenarios, the cost per person treated ranged from $88-

$545, and cost per person correctly treated $117-$623. The main cost drivers for the GeneXpert testing

scenarios were diagnostic costs (up to 87% of total cost) and staff costs (up to 39% of total cost) all other

costs account for less than 1% of total costs. While the base case cost the healthcare system $24 million,

implementing GeneXpert syndromic testing would cost the healthcare system up to $207 million (+761%

more than base case), near-POC opportunistic GeneXpert testing scenarios increase in cost up to $1.7

billion (+7060%) and targeted and/or combined near-POC GeneXpert testing scenarios cost the

healthcare system up to $884 million (+3563%).

Table 3: Epidemiological health outcomes and total cost, cost per person treated and cost per person correctly treated (2024 USD), by

scenario

Scenario	Base case	Near-POC syndromic GeneXpert testing scenarios			Near-POC opportunistic GeneXpert testing scenarios		Combined and/or targeted near-POC GeneXpert testing scenarios			
		S1	S2	S3 ‡	S4	S5	S6	S7	S8	S9
Epidemiological health outcomes										
Total population†	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140	34,336,140
Total syndromic management	1,164,756	0	674,385	0	1,136,045	763,056	1,067,159	0	0	0
Total GeneXpert testing	0	1,164,756	490,371	1,164,756	595,691	11,231,124	2,285,172	1,731,736	3,919,311	4,879,059
Total without STIs	Not examined	251,799	219,102	339,354	368,790	8,674,545	1,439,221	620,589	2,059,810	2,967,806
Total LTFU	0	93,180	39,230	93,180	47,655	898,490	182,814	139,565	318,060	399,090
Total treated	1,164,756	819,776	906,425	732,222	1,315,291	3,115,109	1,845,434	984,410	1,597,877	1,621,725
Total cases correctly treated	837,239	778,753	834,243	694,153	991,632	2,775,355	1,524,310	932,361	1,508,665	1,527,390
Excess antibiotics use	327,517	41,023	72,182	38,069	323,659	339,754	321,125	52,049	89,212	94,335
% change in excess antibiotics use compared to base case	Ref	-87%	-78%	-88%	-1%	4%	-2%	-84%	-73%	-71%
Health system costs										
Consultation - initial visit	$23,264,423	$28,081,169	$25,292,308	$28,081,169	$29,871,724	$151,114,281	$49,023,476	$42,059,792	$95,851,482	$120,270,908
Diagnostic	$0	$156,558,354	$65,912,195	$75,947,886	$80,068,592	$1,512,022,600	$307,957,938	$234,492,078	$534,391,929	$670,535,304
Consultation - results delivery	$0	$21,403,269	$9,010,931	$21,403,269	$3,920,866	$62,858,731	$18,698,734	$32,057,677	$73,057,325	$91,669,639
Treatment	$877,299	$316,724	$572,604	$1,187,230	$908,953	$1,099,469	$1,014,124	$365,908	$530,883	$523,236
Training	$0	$1,405,543	$1,405,543	$1,405,543	$1,405,543	$1,405,543	$1,405,543	$1,405,543	$1,405,543	$1,405,543
Total health system costs	$24,141,723	$207,765,060	$102,193,580	$128,025,098	$116,175,678	$1,728,500,623	$378,099,815	$310,380,998	$705,237,161	$884,404,631
% change in total health system costs compared to base case	Ref	761%	323%	430%	381%	7060%	1466%	1186%	2821%	3563%
Cost per case treated	$21	$253	$113	$175	$88	$555	$205	$315	$441	$545
Cost per case correctly treated	$29	$267	$122	$184	$117	$623	$248	$333	$467	$579

LTFU: lost to follow-up; SM: Syndromic management; POC: Point of care; STI: Sexually transmitted infection
†Total population based on the total underlying population included in the model for each scenario
‡ Testing NG/CT for everyone presenting with VDS/MUS and all receive treatment as per guidelines, this scenario make use of 1 cartridge instead of 2 as it excludes TV.

Cumulative cost and number of GeneXpert tests

To assess the costs and feasibility of scaling up testing strategies, we visualized cumulative costs and

GeneXpert tests performed across all GeneXpert testing scenarios (Fig 2). The size of bubble represents

the cumulative number of cases correctly treated and numbers above or attached to each bubble

represent number of cases correctly treated. Each scenario progressively expands the testing

population, with each patient requiring two tests: one for NG/CT and one for TV. The dotted vertical

line indicates the current annual national testing capacity of 9.7 million tests. We found that all

scenarios, except scenarios 5 (S5) – (Opportunistic testing - HIV testers), and scenario 9 (S9) –

(Syndromic + Opportunistic testing: ANC attendees and HIV testers), are feasible to implement within

the current capacity.

Fig 2. Cumulative cost and number of GeneXpert tests performed by scenario*

*See table 1 for the description of each scenario

Cost-effectiveness

The results of all scenario analysed are included in the Table 4, and of those, only two scenarios were on

the cost-effectiveness frontier. All of these scenarios on the cost-effectiveness frontier resulted in an

increase in total health system costs and the number of cases correctly treated. This include

opportunistic near-POC GeneXpert testing (S5) and targeted and/or combined near-POC GeneXpert

testing scenario (S6). The ICER per additional case correctly treated ranged between $515 to $1,079

(Table 4, Fig 3). Scenarios that are not on the cost-effectiveness frontier were regarded as dominated or

weakly dominated due to resulting in higher total health system costs and fewer number of cases

correctly treated compared to the next best scenario.

Table 4: Total costs, total number of cases correctly treated, ICER and cost-effectiveness of scenarios

that increase number of cases correctly treated

Scenario and descriptions†	Total costs, 2024 USD (% change compared to base case)	Total number of cases correctly treated (% change compared to base case)	ICER per additional case correctly treated (USD) ‡
Base case: Syndromic management: adults aged 15-49 years with STI symptoms seeking STIs care	$24,141,723 (n/a)	837,239 (n/a)	-
S2: GeneXpert testing: all women with STI symptoms seeking care, and syndromic management: all men with STI symptoms seeking care	$102,193,580	834,243	Dominated
S4: GeneXpert testing: all ANC attendees	$116,175,678	991,632	Weakly dominated
S3: GeneXpert testing: all men and women with STI symptoms seeking care (NG/CT testing only)	$128,025,098	694,153	Dominated
S1: GeneXpert testing: all men and women with STI symptoms seeking care	$207,765,060	778,753	Dominated
S7: GeneXpert testing: all men and women with STI symptoms seeking care; all ANC attendees	$310,380,998	932,361	Dominated
S6: GeneXpert testing: women aged 15-24 years presenting for their first HIV test annually and adults aged 15-49 years with STI symptoms seeking STIs care	$378,099,815 (+1466%)	1,524,310 (+82%)	$515 (*compared to base case*)
S8: GeneXpert testing: all men and women with STI symptoms seeking care; all ANC attendees; women aged between 15-24 years presenting for their first HIV test annually	$705,237,161	1,508,665	Dominated
S9: GeneXpert testing: men and women with STI symptoms seeking care; all ANC attendees; men and women aged 15-24 years those presenting for their first HIV test annually	$884,404,631	1,527,390	Weakly dominated

Scenario and descriptions†	Total costs, 2024 USD (% change compared to base case)	Total number of cases correctly treated (% change compared to base case)	ICER per additional case correctly treated (USD) ‡
S5: GeneXpert testing: adults aged 15-49 presenting for their first HIV test annually and adults aged 15-49 years with STI symptoms seeking STIs care	$1,728,674,520 (+7060%)	2,775,355 (+231%)	$1,079

†Scenarios were ordered in ascending order of increasing total health system costs
‡ICERs per additional case correctly treated were calculated by comparing scenarios to the previous scenarios that was on the cost-effective frontier; see details in methods section.

Near-POC GeneXpert testing in women aged 15-24 years presenting for their first HIV test annually and

all syndromic male and females aged 15-49 with STIs symptoms seeking STIs care (S6), resulted in the

increase in number of cases correctly treated by 82% and a 16-fold increase in total health system costs.

compared to base case, S6 resulted in ICER per additional case correctly treated of $515. The most

expensive scenario on the cost-effectiveness frontier was near-POC GeneXpert testing for adults aged

15-49 presenting for their first HIV test annually and all syndromic male and females aged 15-49 with

STIs symptoms seeking STIs care (S5) resulted in an ICER per additional case correctly treated of $1,079

per additional case correctly treated. The number of cases correctly treated increased by 231%.

Implementing this scenario will require an additional budget $1.7 million compared to the base case

(Table 4, Fig 3).

Fig 3. Total cost, total number of cases correctly treated, ICER, and cost-effectiveness of scenarios that

increase number of cases correctly treated

Sensitivity

The sensitivity analysis shows that the cost of cartridge was the most influential input cost parameter for

the ICER per case correctly treated for both scenarios (fig 4). Other parameters that were influential to

the ICER per case correctly treated include sensitivity (VDS/MUS) and EQA. Staff cost, LTFU and training

costs were least influential parameters to the ICER. In the base case sensitivity analysis, staff and

overheads costs were the most influential cost input parameters (S5 figure).

Fig 4. Sensitivity analysis for the ICER per case correctly treated for the scenarios on the cost-

effectiveness frontier*

*The dashed line in fig 4 represent the uncertainty impact on the ICER per case correctly treated under

scenario 5 (**A**) and scenario 6 (**B**).

Budget impact

Table 5 shows the budget impact of the current syndromic management and the scenarios on the cost-

effectiveness frontier over a 5-year period (2025-2029). Under the current base case, the results show

that it will cost the government 25 million to treat individuals presenting with symptoms in 2025 and

which will amount to $145 million in 5-year period. In S5, it would cost the government $1.84 billion to

treat HIV testers with STIs and syndromic individuals seeking STIs care and it is projected to increase by

29% ($2.38 billion) in years 5 (2029) and would amount to $10.52 billion over 5-year period. S6 is

projected to cost the government $2.26 billion over the 5-year period and $399.81 in year 2025 and

$507.30 in year 2029.

Table 5. Budget impact of the base and scenarios on the cost-effectiveness frontier

Year	Base case	Scenario 5	Scenario 6
2025	$25,634,580	$1,843,932,546	$399,808,489
2026	$27,279,675	$1,964,716,262	$424,278,556
2027	$29,067,322	$2,095,967,094	$450,484,323
2028	$31,001,111	$2,235,237,204	$478,358,398
2029	$32,984,245	$2,382,657,792	$507,299,121
Total	**$145,966,933**	**$10,522,510,898**	**$2,260,228,887**

Discussion

In this study, we evaluated the potential impact of reallocating excess GeneXpert capacity for STI

testing, focusing on both cost and health outcomes, including accurate and inaccurate treatment cases.

Our findings highlight that prioritizing symptomatic individuals for testing can reduce unnecessary

antibiotic use, thus providing a potential AMR risk mitigation. Based on current capacity (9.7 million

tests), it would be possible to perform GeneXpert testing (NG/CT and TV) for all ANC attendees and

AGYW HIV testers, with not enough capacity for all HIV testers (S5) and a combination of ANC attendees

and HIV testers (S9) (30). Targeting ANC clinics emerged as a more feasible and beneficial approach for

opportunistic screening compared to broader population-level interventions. Of these, near-POC

GeneXpert testing would not only reduce unnecessary antibiotic use, but also correctly treat more

individuals. While implementing GeneXpert testing for all individuals undergoing HIV testing may be

prohibitively expensive and operationally challenging, focusing on specific high-risk groups, such as

adolescents and young women, offers a more feasible and less costly alternative. These insights

underscore the importance of tailored strategies to maximize both the clinical and economic impact of

GeneXpert deployment for STI management.

Our estimated costs for GeneXpert diagnostics exceeded the current NHLS laboratory cost list for TB

Xpert testing (R465 or $24.90 per test) (51) which also informed prior literature estimates for centralized

NG/CT testing ($28.58 per case diagnosed) (28). This discrepancy is likely explained by the NHLS

subsidizing MTB/XDR Xpert assays. A similar subsidy for STI GeneXpert testing could reduce costs,

suggesting that our estimates—and resulting ICERs—may be overestimated. Smith et al. reported

comparable costs per patient diagnosed with on-site GeneXpert testing ($80.90), though this included

microscopy and represented true POC, i.e. POC testing that is based at the facility and test results are

provided within the patient's time at the facility, rather than near-POC testing (26). Nonetheless,

incremental costs for GeneXpert diagnostics remain high. Several studies have identified strategies to

reduce costs for NG/CT etiological testing, such as using in-house PCR testing (52), pooling samples (53),

conducting GeneXpert testing in centralized laboratories (28), and targeting screening based on risk

factors (54). A mixed approach in Botswana for pregnant women, involving POC at high-volume sites

and centralized laboratories elsewhere, resulted in lower costs per case averted compared to each of

these strategies on their own or syndromic management (27).

Our analysis was limited to the primary outcome of correctly treated cases, without considering

potential downstream effects of correctly, or incorrectly, managing STIs. For example, the analysis could

have been expanded to include broader health outcomes, such as disability-adjusted life years (DALYs),

the number of congenital illnesses prevented, or other STI-related complications avoided. Including

DALYs would have allowed us to compare our incremental cost-effectiveness ratios against relevant

cost-effectiveness thresholds. However, our focus was on the narrower question of South Africa's

current GeneXpert capacity, associated costs, and reductions in excess antibiotic treatments. In this

regard, a limitation is the aggregation of all excess antibiotic treatments, despite stronger evidence of

resistance for some antibiotics compared to others (15,16). Our assumption of 9.7 million available tests

nation-wide also has limitations, as it does not account for sub-national capacity variations, nor do we

consider the potential impact of scaling up other GeneXpert testing strategies, such as for TB or HPV.

Further, we were limited by our choice of having a static model, which does not capture the

transmission dynamics of STIs, including the risk of reinfection and the impact of treating sexual

partners. These limitations suggest our findings may underestimate the broader public health benefits

or challenges associated with STI testing strategies. Our findings underscore the role of STI screening

strategies in mitigating antibiotic overuse and addressing AMR. Given the substantial economic burden

of AMR, often exceeding their purchase cost (estimated cost associated with the consumption of one

standard unit of antibiotics range: $0.01-0.07) (55), incorporating the economic burden of AMR through

a "AMR penalty cost" could significantly reduce the ICERs of advanced screening technologies and

costlier treatments with lower resistance potential (19). However, this analysis did not account for the

broader economic and public health impacts of AMR because AMR-related costs specific to STIs and the

South African context remain unquantified and were beyond the scope of this study. Finally, our

scenarios assume that all people receiving opportunistic GeneXpert testing do not subsequently seek

care at PHCs as part of the syndromic population. This assumption may lead to an underestimation of

both cost and case estimates. However, as both costs and outcomes are likely underestimated in the

same direction, the overall impact on ICERs may be minimal.

Our analysis focused on the public healthcare sector in South Africa and was conducted at the national

level. As such, while our findings are generalizable within South Africa, their transferability to other Sub-

Saharan African countries is limited. South Africa's early adoption of GeneXpert in 2011, supported by

national and donor funding, established a robust laboratory infrastructure, reflected in our cost

estimates from centralized labs (29). In contrast, other SSA settings often face higher implementation

costs due to infrastructure challenges, such as space and power requirements, and greater training

needs (56). South Africa's experienced NHLS workforce minimizes training expenses, unlike contexts

requiring significant workforce capacity building. Additionally, South Africa's relatively low reliance on

donor funding allows its health system greater autonomy in setting priorities, unlike many SSA countries

where donor influence shapes health agendas (57,58). These differences highlight the need for country-

specific strategies for GeneXpert placement, considering infrastructure, workforce readiness, and

financing capacity to ensure cost-effective implementation.

Our study highlights several policy implications and directions for future research. Our analysis found

that overall, switching to GeneXpert testing will be very costly compared to the current strategy of

syndromic management. These budgetary impacts will require a shift of resources from other health

priorities to STI management. While we focused on repurposing existing GeneXpert capacity from

MTB/RIF testing to NG/CT or TV testing, GeneXpert has broader diagnostic potential. Additional

applications include screening for human papillomavirus (HPV), herpes simplex virus (HSV-1 and HSV-2),

HIV and Hepatitis B and C viral load monitoring, and detection of methicillin-resistant Staphylococcus

aureus (MRSA), Group B Streptococcus in pregnancy (59). This is particularly relevant as alternative

rapid and POC diagnostics for NG are advancing, including lateral flow assays and rapid tests (60,61).

Moreover, other POC tools for STIs are under development, such as the GIFT screening tool for bacterial

vaginosis (BV) (26,62) OSAM-TV for TV (63), and the BD Affirm VPIII assay for BV, TV, and Candida (64).

Future research should investigate how alternative diagnostics compare to or complement GeneXpert to

ensure cost-effective and sustainable approaches for managing sexually transmitted infections across

diverse settings. Considering that cervical cancer is the leading cancer among women in South Africa

(65), prioritizing research on the application of GeneXpert for HPV screening is a logical next step.

Additionally, extending cost-effectiveness models for GeneXpert testing—whether for STIs or other

diseases—to incorporate longer-term health and economic outcomes would provide more

comprehensive insights for policymaking and resource allocation.

Conclusions

With ongoing challenges of current STIs syndromic management in South Africa, our study highlighted

the potential impact of reallocating excess GeneXpert capacity for STI testing to enhance diagnostic

accuracy and improve health outcomes in South Africa. Prioritizing symptomatic individuals and high-

risk groups, such as HIV testers, can reduce unnecessary antibiotic use, addressing antimicrobial

resistance challenges. These findings support the need for targeted and context-specific strategies to

optimize the clinical and economic benefits of GeneXpert deployment for STI management. However,

while our analysis shows improvements in health outcomes, adoption of near-point GeneXpert of care

services may require considerable budgetary investment.

Supporting information

S1 Table. Search Strategy for model parameter inputs

S2 Figure. Underlying population for the base case and each of the scenario

S3 Table. STI treatment regimens and associated costs

S4 Table. Testing scenario costs per patient (2024 USD)

S5 Figure. Sensitivity analysis of cost per case correctly treated under base case scenario

Declaration of interests

We declare no competing interests.

Authors contributions

NL, KS, LJ and BEN conceptualised the study. NL, KS and LJ did the literature reviews and compiled data

for model parameterisation. NL and KS collected cost data. LJ oversaw data collection and

parameterisation. NL developed the model and model structure. NL did the data analysis. NL, KS, and LJ

had full access to all data in the study. LJ and BEN verified underlying data and assumptions. All authors

contributed to reviewing and editing the manuscript for submission.

Funding

This study was funded by FIND (FIND contract number: XC22-0197).

Role of the funding source

Data availability statement

We acknowledge the importance of transparent and responsible data sharing to foster scientific

collaboration and advance research. The data used for this study were collected from publicly available

sources, previously published literature and do not contain any identifying information. The

corresponding author - NL (nlekodeba@heroza.org) may be contacted by interested parties for further

information.

References

1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually

transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021:

actions for impact. Geneva; 2021.

2. Zheng Y, Yu Q, Lin Y, Zhou Y, Lan L, Yang S, et al. Global burden and trends of sexually

transmitted infections from 1990 to 2019: an observational trend study. Lancet Infect Dis. 2022

Apr;22(4):541–51.

3. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia,

gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull

World Health Organ. 2019 Aug 1;97(8):548-562P.

4. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JAR, Ramon-Pardo P, et al. Antimicrobial resistance in

Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS

Med. 2017 Jul 7;14(7):e1002344.

5. Peters R, Klausner J, de Vos L, Feucht U, Medina-Marino A. Aetiological testing compared with

syndromic management for sexually transmitted infections in HIV-infected pregnant women in

South Africa: a non-randomised prospective cohort study. BJOG. 2021 Jul 22;128(8):1335–42.

6. Jarolimova J, Chidumwa G, Chimbindi N, Okesola N, Dreyer J, Smit T, et al. Prevalence of

Curable Sexually Transmitted Infections in a Population-Representative Sample of Young Adults

in a High HIV Incidence Area in South Africa. Sex Transm Dis. 2023 Dec;50(12):796–803.

7. De Voux A, Mvududu R, Happel A, Jaspan HB, Nyemba DC, Mashele N, et al. Point-of-Care

Sexually Transmitted Infection Testing Improves HIV Preexposure Prophylaxis Initiation in

Pregnant Women in Antenatal Care in Cape Town, South Africa, 2019 to 2021. Sex Transm Dis.

2023 Feb 1;50(2):92–7.

8. Green H, Taleghani S, Nyemba D, Myer L, Davey DJ. Partner notification and treatment for

sexually transmitted infections among pregnant women in Cape Town, South Africa. Int J STD

AIDS. 2020 Nov 1;31(13):1282–90.

9. Delany-Moretlwe S, Mgodi N, Bekker LG, Baeten JM, Li C, Donnell D, et al. High prevalence and

incidence of gonorrhoea and chlamydia in young women eligible for HIV pre-exposure

prophylaxis in South Africa and Zimbabwe: Results from the HPTN 082 trial. Sex Transm Infect.

2023 Nov 1;99(7):433–9.

10. Davey JNDC, Gomba Y, Bekker LG, Taleghani S, DiTullio DJ, Shabsovich D, et al. Prevalence and

correlates of sexually transmitted infections in pregnancy in HIV-infected and- uninfected women

in Cape Town, South Africa. PLoS One. 2019 Jul 1;14(7):e0218349.

11. Kharsany ABM, McKinnon LR, Lewis L, Cawood C, Khanyile D, Maseko DV, et al. Population

prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal,

South Africa: Implications for HIV epidemic control. International Journal of Infectious Diseases

[Internet]. 2020 Sep 1 [cited 2024 Oct 28];98:130–7. Available from:

http://www.ijidonline.com/article/S1201971220304811/fulltext

12. Statistics South Africa. Mid-year population report, 2024 (P0302). 2024.

13. World Health Organization. Sexually transmitted infections fact sheet [Internet]. 2024 [cited

2024 Dec 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/sexually-

transmitted-infections-(stis)

14. Raccagni AR, Ranzenigo M, Bruzzesi E, Maci C, Castagna A, Nozza S. Neisseria gonorrhoeae

Antimicrobial Resistance: The Future of Antibiotic Therapy. J Clin Med. 2023 Dec 18;12(24):7767.

15. Yakobi SH, Magibile YB, Pooe OJ. A systematic review of Neisseria gonorrhoeae drug

resistance development in South Africa. Brazilian Journal of Microbiology. 2024 Jun

25;55(2):1053–63.

16. Mabaso N, Abbai NS. A review on Trichomonas vaginalis infections in women from Africa. S

Afr J Infect Dis. 2021 Jun 10;36(1).

17. South Africa National Department of Health. Comprehensive STI Clinical Management

Guidelines. 2021.

18. Mlisana K, Naicker N, Werner L, Roberts L, Van Loggerenberg F, Baxter C, et al. Symptomatic

vaginal discharge is a poor predictor of sexually transmitted infections and genital tract

inflammation in high-risk women in South Africa. Journal of Infectious Diseases. 2012 Jul

1;206(1):6–14.

19. Ayinde O, Ross JDC, Jackson L. Economic evaluation of antimicrobial resistance in curable

sexually transmitted infections; a systematic review and a case study. PLoS One. 2023 Oct

1;18(10 October).

20. World Health Organization. Global health sector strategies on, respectively, HIV, viral

hepatitis and sexually transmitted infections for the period 2022-2030 [Internet]. Geneva; 2022

[cited 2024 Dec 2]. Available from:

https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf?sequence=1

21. Saweri OPM, Batura N, Al Adawiyah R, Causer LM, Pomat WS, Vallely AJ, et al. Economic

evaluation of point-of-care testing and treatment for sexually transmitted and genital infections

in pregnancy in low- And middle-income countries: A systematic review. Vol. 16, PLoS ONE.

Public Library of Science; 2021.

22. Zhang M, Zhang H, Hui X, Qu H, Xia J, Xu F, et al. The cost-effectiveness of syphilis screening in

pregnant women: a systematic literature review. Vol. 12, Frontiers in Public Health. Frontiers

Media SA; 2024.

23. Silke F, Earl L, Hsu J, Janko MM, Joffe J, Memetova A, et al. Cost-effectiveness of interventions

for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.

Lancet Glob Health. 2024 Jul 1;12(7):e1159–73.

24. Khumalo F, Passmore JAS, Manhanzva M, Meyer B, Duyver M, Lurie M, et al. Shifting the

power: scale-up of access to point-of-care and self-testing for sexually transmitted infections in

low-income and middle-income settings. Curr Opin Infect Dis. 2023 Feb;36(1):49–56.

25. Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, et al. Diagnosing sexually

transmitted infections in resource-constrained settings: challenges and ways forward. J Int AIDS

Soc. 2019 Aug 30;22(S6).

26. Smith E, Masson L, Passmore JAS, Sinanovic E. Cost-effectiveness analysis of different

screening and diagnostic strategies for sexually transmitted infections and bacterial vaginosis in

women attending primary health care facilities in Cape Town. Front Public Health. 2023 Mar

2;11.

27. Wynn A, Moucheraud C, Martin NK, Morroni C, Ramogola-Masire D, Klausner JD, et al.

Bridging the Gap between Pilot and Scale-Up: A Model of Antenatal Testing for Curable Sexually

Transmitted Infections from Botswana. Sex Transm Dis. 2022 Jan 1;49(1):59–66.

28. Marcus R, C P, Gill K, Smith P, Rouhani S, Mendelsohn A, et al. Acceptability, feasibility and

cost of point of care testing for sexually transmitted infections among South African adolescents

where syndromic management is standard of care. BMC Health Serv Res. 2023 Dec 1;23(1).

29. da Silva MP, Cassim N, Ndlovu S, Marokane PS, Radebe M, Shapiro A, et al. More Than a

Decade of GeneXpert® Mycobacterium tuberculosis/Rifampicin (Ultra) Testing in South Africa:

Laboratory Insights from Twenty-Three Million Tests. Diagnostics. 2023 Oct 19;13(20):3253.

30. National Health Laboratory Service. Annual Report 2022-2023 [Internet]. 2023 [cited 2024

Jun 1]. Available from: https://www.nhls.ac.za/wp-content/uploads/2023/11/241023-NHLS-

Annual_Report.pdf

31. Cepheid. Xpert TV [Internet]. 2024 [cited 2024 Jun 1]. Available from:

https://www.cepheid.com/en-GB/tests/blood-virology-womens-health-sexual-health/xpert-

tv.html

32. Cepheid. Xpert CT/NG [Internet]. 2024 [cited 2024 Jun 1]. Available from:

https://www.cepheid.com/en-GB/tests/blood-virology-womens-health-sexual-health/xpert-ct-

ng.html

33. Frank D, Kufa T, Dorrell P, Kularatne R, Maithufi R, Chidarikire T, et al. Evaluation of the

national clinical sentinel surveillance system for sexually transmitted infections in South Africa:

Analysis of provincial and district-level data. South African Medical Journal [Internet]. 2023 Jul 5

[cited 2024 Oct 28];113(7):41–8. Available from:

https://samajournals.co.za/index.php/samj/article/view/365

34. Xie TA, Liu YL, Meng RC, Liu XS, Fang KY, Deng ST, et al. Evaluation of the Diagnostic Efficacy

of Xpert CT/NG for Chlamydia trachomatis and Neisseria gonorrhoeae. Biomed Res Int. 2020 Oct

8;2020:1–16.

35. Schwebke JR, Gaydos CA, Davis T, Marrazzo J, Furgerson D, Taylor SN, et al. Clinical Evaluation

of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively

Collected Specimens from Men and Women. J Clin Microbiol. 2018 Feb;56(2).

36. Johnson LF, Dorrington R. Thembisa Version 4.7: A Model for Evaluating the Impact of

HIV/AIDS in South Africa. [Internet]. 2024 [cited 2024 Jun 1]. Available from:

https://thembisa.org/content/downloadPage/Thembisa4_7report

37. Statistics South Africa. Recorded Live Births 2023 (P0305) [Internet]. 2024 [cited 2024 Dec 5].

Available from: https://www.statssa.gov.za/publications/P0305/P03052023.pdf

38. Cutland CL, Sawry S, Fairlie L, Barnabas S, Frajzyngier V, Roux J Le, et al. Obstetric and

neonatal outcomes in South Africa. Vaccine. 2024 Feb;42(6):1352–62.

39. South Africa National Department of Health, Statistics South Africa, South African Medical

Research Council. Demographic and Health Survey 2016 Key Findings [Internet]. 2018. Available

from: www.DHSprogram.com.

40. Travill D, Machemedze D, Zwane P, Mokhele T, Makhale L, Sokhela Z, et al. Same day testing

and treatment for STIs in adolescents: results of a pilot randomised controlled trial in South

Africa. In: 5th HIV Research for Prevention Conference [Internet]. Munich; 2024 [cited 2024 Dec

2]. Available from: https://programme2024.hivr4p.org/Abstract/Abstract/?abstractid=1553

41. Kufa-Chakezha T, Shangase N, Lombard C, Manda S, Puren A. The 2022 Antenatal HIV Sentinel

Survey [Internet]. 2023 [cited 2024 Dec 12]. Available from: https://www.nicd.ac.za/wp-

content/uploads/2024/01/Antenatal-survey-2022-

report_National_Provincial_12Jul2023_Clean_01.pdf

42. Long LC, Girdwood S, Govender K, Meyer-Rath G, Miot J. Cost and outcomes of routine HIV

care and treatment: public and private service delivery models covering low-income earners in

South Africa. BMC Health Serv Res. 2023 Mar 11;23(1):240.

43. Cassim N, Omar SV, Masuku SD, Moultrie H, Stevens WS, Ismail F, et al. Xpert MTB/XDR

implementation in South Africa: cost outcomes of centralised vs. decentralised approaches. IJTLD

OPEN. 2024 May 14;1(5):215–22.

44. FIND. Cepheid pricing – FIND DxConnect Marketplace [Internet]. 2024 [cited 2024 Oct 28].

Available from: https://dxc-marketplace.finddx.org/pages/cepheid-accessible-pricing

45. STATSSA. CPI headline year-on-year rates [Internet]. 2024 [cited 2024 Oct 29]. Available from:

https://www.statssa.gov.za/publications/P0141/CPIHistory.pdf?

46. South African Reserve Bank. Current Market Rates [Internet]. 2024 [cited 2024 Oct 29].

Available from: https://www.resbank.co.za/en/home/what-we-do/statistics/key-

statistics/current-market-rates

47. South Africa Department of Public Service and Administration. Salary scales, with translation

keys, for employees of salary levels 1 to 12 and those employees covered by Occupation Specific

Dispensations (OSDs) [Internet]. 2024 [cited 2024 Dec 2]. Available from:

https://www.dpsa.gov.za/policy-

updates/nlrrm/remuneration_policy/annual_cost_of_living_adjustments/

48. South Africa National Department of Health. 2030 Human Resources for Health Strategy:

Investing in the Health Workforce for Universal Health Coverage [Internet]. Pretoria; 2020 [cited

2024 Dec 5]. Available from: https://www.health.gov.za/wp-content/uploads/2023/06/2030-

HRH-Strategy-Final.pdf

49. World Health Organization. Updated recommendations for the treatment of Neisseria

gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new

recommendations on syphilis testing and partner services [Internet]. 2024 [cited 2024 Nov 21].

Available from: https://www.who.int/publications/i/item/9789240090767

50. South Africa National Department of Health. Current Master Health Product List February

2024 [Internet]. 2024 Feb [cited 2024 Jun 6]. Available from: https://www.health.gov.za/tenders/

51. National Health Laboratory System. NHLS State Price List 2023/24 [Internet]. 2023 [cited 2024

Dec 5]. Available from: https://www.nhls.ac.za/

52. Dos Santos CG, Sabidó M, Leturiondo AL, De Oliveira Ferreira C, Da Cruz TP, Benzaken AS.

Development, validation and testing costs of an in-house realtime PCR assay for the detection of

Chlamydia trachomatis. J Med Microbiol. 2017 Mar 1;66(3):312–7.

53. Connolly S, Kilembe W, Inambao M, Visoiu AM, Sharkey T, Parker R, et al. A population-

specific optimized genexpert pooling algorithm for chlamydia trachomatis and neisseria

gonorrhoeae to reduce cost of molecular sexually transmitted infection screening in resource-

limited settings. J Clin Microbiol. 2020 Sep 1;58(9).

54. McCartney DJ, Luppi CG, Silva RJC, De Araújo S, Bassichetto KC, Mayaud P, et al. Anorectal

gonorrhoea and chlamydia among transgender women in Brazil: Prevalence and assessment of

performance and cost of anorectal infection detection and management approaches. Sex Transm

Infect. 2023;

55. Shrestha, P., Cooper, B.S., Coast, J. *et al.* Enumerating the economic cost of antimicrobial

resistance per antibiotic consumed to inform the evaluation of interventions affecting their

use. *Antimicrob Resist Infect Control* **7**, 98 (2018). https://doi.org/10.1186/s13756-018-0384-3

56. Abdurrahman ST, Emenyonu N, Obasanya OJ, Lawson L, Dacombe R, Muhammad M, et al.

The hidden costs of installing xpert machines in a tuberculosis high-burden country: experiences

from Nigeria. Pan African Medical Journal. 2014;18.

57. James C, Gmeinder M, María A, Rivadeneria R, Vammalle C, Blecher M, et al. Health financing

and budgeting practices for health in South Africa. OECD Journal on Budgeting. 2018;2017(3).

58. Agyei E, Kumah E. Navigating the complex terrain of healthcare systems in Sub-Saharan

Africa: challenges and opportunities for progress. Discover Health Systems. 2024 Jun 20;3(1):39.

59. Cepheid. Molecular Diagnostic Testing Menu [Internet]. 2024 [cited 2024 Dec 9]. Available

from: https://www.cepheid.com/en-US/tests.html

60. de Vos L, Daniels J, Gebengu A, Mazzola L, Gleeson B, Piton J, et al. Usability of a novel lateral

flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series

assessment among healthcare workers in South Africa. PLoS One. 2023 Jun 1;18(6 June).

61. Peters RPH, Klausner JD, Mazzola L, Mdingi MM, Jung H, Gigi RMS, et al. Novel lateral flow

assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management

settings: a cross-sectional performance evaluation. The Lancet. 2024 Feb 17;403:657–64.

62. Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, et al. Impact of Point-of-Care

Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the

HVTN702 Human Immunodeficiency Virus Vaccine Trial. Clinical Infectious Diseases. 2023 Mar

1;76(5):881–9.

63. Garrett N, Mitchev N, Osman F, Naidoo J, Dorward J, Singh R, et al. Diagnostic accuracy of the

Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young

women in South Africa: A cross-sectional study. BMJ Open. 2019 Feb 1;9(2).

64. Dessai F, Nyirenda M, Sebitloane M, Abbai N. Diagnostic evaluation of the BD Affirm VPIII

assay as a point-of-care test for the diagnosis of bacterial vaginosis, trichomoniasis and

candidiasis. Int J STD AIDS. 2020 Mar 12;31(4):303–11.

65. Statistics South Africa. Cancer in South Africa [Internet]. Pretoria; 2023 [cited 2024 Dec 11].

Available from: https://www.statssa.gov.za/publications/03-08-00/03-08-002023.pdf